

RECEIVED
CENTRAL FAX CENTER

APR 8 2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re Application of
Tahir Nadeem Majid, et al.

Examiner: Huang, Evelyn Mei

Serial No.: 10/613,588

Art Unit: 1625

Filed: July 03, 2003

TELEFAX CERTIFICATEI hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, Alexandria, VA 22313, at (703) 872-9306 onTitle: PYRAZOLOISQUINOLINE
DERIVATIVES AS KINASE
INHIBITORS

Date of transmission

Signature

TERMINAL DISCLAIMER

Commissioner for Patents

Washington, D.C. 20231

Sir:

The petitioner, Aventis Pharmaceuticals Inc., a fully owned subsidiary of Aventis Pharma S. A., having offices at 300 Somerset Corporate Boulevard, Bridgewater, NJ 08807, represents that it is the assignee of Application Serial No. 10/613,588, filed on July 03, 2003, by an assignment which is being concurrently recorded at the USPTO, a copy of the assignment is enclosed herewith.

The petitioner, Aventis Pharmaceuticals Inc., hereby disclaims the terminal part of any patent granted on the above-identified application, which would extend beyond the expiration date of United States Patent No. 6,841,556, issued on January 11, 2005, which is assigned to and commonly owned by Aventis Pharma Deutschland GmbH, a fully owned subsidiary of Aventis Pharma S.A., and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to aforementioned U. S. Patent No. 6,841,556, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors or assigns.

Such disclaimer does not, however, mean that petitioner hereby waives or disclaims any right to an extension of the term of any patent issuing from application serial number 10/613,588, under 35 USC §§ 155 to 156, pursuant to (a) Title II of Pub. L. No. 98-417, enacted on September 24, 1984, and entitled the "Drug Price Competition and Patent Term Restoration Act of 1984", (b) Pub. 98-417, enacted on September 24, 1984, and entitled the "Drug Price Competition and Patent Term Restoration Act of 1984", (b) Pub. L. No. 100-670, enacted November 16, 1988 and entitled "Patent

Docket No. USAV2003/0110 US NP

-1-

See Responses
Only

04/10/2005 11:49:45 AM 10613588

01 APR 14 130-05-20

Term Extension for Animal Drug Products", or (c) any other subsequently enacted Public Law or Act which provides for the extension of the term of a patent.

Such disclaimer does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term, as presently shortened by any terminal disclaimer of U. S. Patent No. 6,841,556 in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321(a), has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to the expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title as stated above.

For submissions on behalf of Aventis Pharmaceuticals Inc., the undersigned is empowered to act on behalf of the organization. Enclosed is a Statement under 37 C.F.R. 3.73(b) Establishing Right of Assignee to Take Action.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Please charge Deposit Account No. 18-1982 in the amount of \$130.00. The Commissioner is authorized to charge any fees under 37 CFR 1.16 - 1.21 or credit any overpayment to Account No. 18-1982.

Signed at Bridgewater, New Jersey, U.S.A., this 8th day of April, 2005.

Respectfully submitted,



Balaram Gupta, Reg. No. 40,009
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3364
Telefax (908) 231-2626